Oral and subcutaneous semaglutide show identical cardiovascular efficacy in 4-trial meta-analysis | Research

The takeaway

Meta-analysis of 4 RCTs (19,663 T2DM patients) confirms semaglutide reduces primary CV outcome by 17% (HR 0.83), nonfatal MI by 21% (HR 0.79), and revascularization by 29% (HR 0.71), with identical efficacy between oral and subcutaneous formulations.

Oral = injectable for heart protection
Meta-analysis confirms oral and subcutaneous semaglutide provide identical cardiovascular protection—patients can choose pills without compromising heart outcomes

What the researchers found

Primary CV outcome: HR 0.83 (0.76-0.91). Nonfatal MI: HR 0.79 (0.67-0.92). Revascularization: HR 0.71 (0.61-0.83). HF hospitalization: HR 0.85 (0.72-1.00). CV death, all-cause death, stroke: NS. Oral = subcutaneous efficacy. 4 RCTs, 19,663 patients. GRADE: moderate-high.

Why it matters

Confirming oral semaglutide provides identical cardiovascular protection as injectable removes a key prescribing uncertainty. Patients can choose pill or injection without compromising heart protection.

How the study worked

PROSPERO-registered meta-analysis (CRD420251147337). PubMed, Embase, Cochrane, Web of Science. 4 RCTs. Fixed/random effects. Sensitivity, subgroup, GRADE analyses.

What this study cannot tell us

4 trials only. Different trial populations. Cannot determine if dose equivalence is maintained across all CV outcomes. Mortality not significantly reduced.

How to read the evidence

Meta-analysis of 4 RCTs with GRADE assessment (moderate-high). Strong evidence.

When this study was published

Published in 2025.

The bigger picture

This is the definitive formulation comparison for semaglutide cardiovascular efficacy. Oral GLP-1 therapy is now confirmed as cardiovascularly equivalent to injection—potentially shifting millions of patients to pills.

Questions still open

Will oral semaglutide receive a formal CV indication?
Should oral be preferred over injectable for new patients?
Does the oral formulation's lower bioavailability matter for CV protection?

Common questions

Does oral semaglutide protect the heart as well as injections?

Yes. This meta-analysis of nearly 20,000 patients confirms that oral semaglutide pills provide identical cardiovascular protection to subcutaneous injections. Both reduce heart attacks by 21% and the need for heart procedures by 29%.

Should I switch from injectable to oral semaglutide?

Based on cardiovascular efficacy, you can safely choose either formulation. Oral may be preferred for convenience (no injections), while injectable may be preferred for patients who cannot manage the oral dosing requirements (empty stomach, 30-minute wait). Heart protection is the same.

Read the original research

Effects of subcutaneous or oral semaglutide on cardiovascular outcomes in patients with type 2 diabetes mellitus: a meta-analysis of randomized controlled trials.

Frontiers in cardiovascular medicine, 12, 1731127

View on PubMed ↗Publisher’s paper ↗

Citation

Tan, Sihua; Yin, Yangguang; Lu, Juexiu. (2025). Effects of subcutaneous or oral semaglutide on cardiovascular outcomes in patients with type 2 diabetes mellitus: a meta-analysis of randomized controlled trials.. Frontiers in cardiovascular medicine, 12, 1731127. https://doi.org/10.3389/fcvm.2025.1731127